Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey-Reference-Cited by-同舟云学术

Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey

Published:2022-01 Issue:1 Volume:5 Page:
ISSN:2398-8835
Container-title:Health Science Reports
language:en
Short-container-title:Health Science Reports

Author:

Caseby Sophie Clare Laura¹^ORCID,Woodhouse Fern Amy²^ORCID,Montgomery Stephen Maxwell²^ORCID,Kroes Michel Anton³,Duddy Martin Edward⁴^ORCID

Affiliation:

1. Market Access Division Costello Medical London UK

2. HTA Division Costello Medical Cambridge UK

3. Health Economics and Outcomes Research Novartis Pharmaceuticals UK Limited London UK

4. Department of Neurology Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne UK

Funder

Novartis Pharmaceuticals UK Limited

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hsr2.474

Reference27 articles.

1. Multiple Sclerosis Trust.Prevalence and incidence of multiple sclerosis.2020.https://www.mstrust.org.uk/a-z/prevalence-and-incidence-multiple-sclerosis. Accessed December 09 2020.

2. Defining the clinical course of multiple sclerosis: The 2013 revisions

3. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

4. NICE.Multiple sclerosis in adults: management (CG186).2014.https://www.nice.org.uk/guidance/cg186/resources/multiple-sclerosis-in-adults-management-pdf-35109816059077. Accessed December 09 2020.

5. Multiple challenges for people after transitioning to secondary progressive multiple sclerosis: a qualitative study

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis;Multiple Sclerosis Journal;2024-02-19

2. Estimating the disutility of relapse in relapsing–remitting and secondary progressive multiple sclerosis using the EQ-5D-5L, AQoL-8D, EQ-5D-5L-psychosocial, and SF-6D: implications for health economic evaluation models;Quality of Life Research;2023-07-31

3. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK;Journal of Medical Economics;2022-05-27